Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Oct;5(4):601-6.
doi: 10.1016/j.nurt.2008.07.005.

Facioscapulohumeral muscular dystrophy

Rabi Tawil  1
Affiliations
Review

Facioscapulohumeral muscular dystrophy

Rabi Tawil. Neurotherapeutics. 2008 Oct.

Abstract

Facioscapulohumeral muscular dystrophy (FSHD), a dominantly inherited disorder, is the third most common dystrophy after Duchenne and myotonic muscular dystrophy. No known effective treatments exist for FSHD. The lack of an understanding of the underlying pathophysiology remains an obstacle in the development of targeted therapeutic interventions. The genetic defect is a loss of a critical number of a repetitive element (D4Z4) in the 4q subtelomeric region. The loss of the repeats results in specific changes in chromatin structure, although neither the molecular nor the cellular consequences of this change are known. Nevertheless, these epigenetic changes in chromatin structure offer a potential therapeutic target. This review discusses current management strategies in FSHD as well as potential therapeutic interventions to slow down or reverse the progressive muscle atrophy and weakness.

PubMed Disclaimer

Similar articles

  • Facioscapulohumeral muscular dystrophy (FSHD): an enigma unravelled?
    Richards M, Coppée F, Thomas N, Belayew A, Upadhyaya M. Richards M, et al. Hum Genet. 2012 Mar;131(3):325-40. doi: 10.1007/s00439-011-1100-z. Epub 2011 Oct 9. Hum Genet. 2012. PMID: 21984394 Review.
  • Facioscapulohumeral dystrophy.
    Pandya S, King WM, Tawil R. Pandya S, et al. Phys Ther. 2008 Jan;88(1):105-13. doi: 10.2522/ptj.20070104. Epub 2007 Nov 6. Phys Ther. 2008. PMID: 17986494 Review.
  • Facioscapulohumeral Muscular Dystrophy.
    Statland JM, Tawil R. Statland JM, et al. Continuum (Minneap Minn). 2016 Dec;22(6, Muscle and Neuromuscular Junction Disorders):1916-1931. doi: 10.1212/CON.0000000000000399. Continuum (Minneap Minn). 2016. PMID: 27922500 Free PMC article. Review.
  • Facioscapulohumeral muscular dystrophy.
    Tawil R. Tawil R. Handb Clin Neurol. 2018;148:541-548. doi: 10.1016/B978-0-444-64076-5.00035-1. Handb Clin Neurol. 2018. PMID: 29478599 Review.
  • Facioscapulohumeral muscular dystrophy.
    van der Maarel SM, Frants RR, Padberg GW. van der Maarel SM, et al. Biochim Biophys Acta. 2007 Feb;1772(2):186-94. doi: 10.1016/j.bbadis.2006.05.009. Epub 2006 Jun 6. Biochim Biophys Acta. 2007. PMID: 16837171 Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Padberg GW. Facioscapulohumeral disease. Leiden, The Netherlands: University of Leiden; 1982.
    1. Wohlgemuth M, van der Kooi EL, van Kesteren RG, van der Maarel SM, Padberg GW. Ventilatory support in facioscapulohumeral muscular dystrophy. Neurology. 2004;63:176–178. doi: 10.1212/01.WNL.0000133126.86377.E8. - DOI - PubMed
    1. Fitzsimons RB, Gurwin EB, Bird AC. Retinal vascular abnormalities in facioscapulohumeral muscular dystrophy: a general association with genetic and therapeutic implications. Brain. 1987;110:631–648. doi: 10.1093/brain/110.3.631. - DOI - PubMed
    1. Padberg GW, Brouwer OF, de Keizer RF, et al. On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy. Muscle Nerve 1995:S73–S80. - PubMed
    1. Shields CL, Zahler J, Falk N, et al. Neovascular glaucoma from advanced Coats disease as the initial manifestation of facioscapulohumeral dystrophy in a 2-year-old child. Arch Ophthalmol. 2007;125:840–842. doi: 10.1001/archopht.125.6.840. - DOI - PubMed

MeSH terms